Patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and insulin resistance may experience improvements in hepatic steatosis and liver enzyme elevations, though this represents an off-label use with evolving evidence
Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ, Lopez-Jimenez F
Semaglutide works as a medical tool that supports health goals rather than replacing fundamental lifestyle practices
Prescription weight loss treatment is more common now than ever before, which is a massive step in the right direction in handling the obesity epidemic
GLP-1 Showdown: Inside The High Stakes War over Patients Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies
(2021) 45:e13810